With increasing time since diagnosis, only the severe infections continued to cause symptoms.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
(CIDRAP News) – Experts from the US Centers for Disease Control and Prevention (CDC) and the National Influenza Vaccine Summit (NIVS) in a teleconference today urged clinicians to consider extending their seasonal flu vaccination efforts through March and shared strategies for immunizing more patients during office visits.
Editor's Note: CIDRAP's Promising Practices: Pandemic Influenza Preparedness Tools online database showcases peer-reviewed practices, including useful tools to help others with their planning. This article is one of a biweekly series exploring the development of these practices. We hope that describing the process and context of these practices enhances pandemic planning.
(CIDRAP News) – The US Department of Health and Human Services (HHS) has released a toolkit to help community leaders educate their constituents about steps they can take to prepare for an influenza pandemic.
(CIDRAP News) The US Food and Drug Administration's (FDA's) Pediatric Advisory Committee voted today to recommend stronger label warnings for two antiviral influenza medicationsoseltamivir and zanamivirthat have been linked to reports of neuropsychiatric problems in children and teens, mainly in Japan.
Oseltamivir already carries a warning, but zanamivir currently carries no warning about reported neuropsychiatric effects.
(CIDRAP News)
Introductory remarksJohn Barry's commentary
(CIDRAP News) A World Health Organization (WHO) group that recently met to work out an agreement to ease the global sharing of H5N1 avian influenza viruses failed to resolve the issue, but signaled that work on the issues would continue.
Editor's Note: This article is one of an occasional series exploring the development of public health practices included in the CIDRAP Promising Practices: Pandemic Influenza Preparedness Tools online database. We hope that describing the process and context that drove development of these practices serves as a valuable tool for pandemic planning.
Editor's note: This article was originally published in CIDRAP News as a seven-part series running from October 25 through November 2, 2007. It investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
Maryn McKennaContributing Writer
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.
(CIDRAP News) Adults who are hospitalized with serious seasonal influenza infections are more likely to survive if they receive antiviral medications, and older patients may benefit even if treatment is delayed until more than 48 hours after their first symptoms, according to a new study by Canadian researchers.
